These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30869898)

  • 1. Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments.
    Arrington J; Xue L; Wang WH; Geahlen RL; Tao WA
    J Proteome Res; 2019 Apr; 18(4):1679-1690. PubMed ID: 30869898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
    Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates.
    Xue L; Wang WH; Iliuk A; Hu L; Galan JA; Yu S; Hans M; Geahlen RL; Tao WA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5615-20. PubMed ID: 22451900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase Assay-Linked Phosphoproteomics: Discovery of Direct Kinase Substrates.
    Arrington JV; Hsu CC; Tao WA
    Methods Enzymol; 2017; 586():453-471. PubMed ID: 28137576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
    Liang X; Hajivandi M; Veach D; Wisniewski D; Clarkson B; Resh MD; Pope RM
    Proteomics; 2006 Aug; 6(16):4554-64. PubMed ID: 16858728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.
    Toman O; Kabickova T; Vit O; Fiser R; Polakova KM; Zach J; Linhartova J; Vyoral D; Petrak J
    Oncol Rep; 2016 Sep; 36(3):1258-68. PubMed ID: 27430982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
    Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
    Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Direct Kinase Substrates via Kinase Assay-Linked Phosphoproteomics.
    Xue L; Arrington JV; Tao WA
    Methods Mol Biol; 2016; 1355():263-73. PubMed ID: 26584932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of direct tyrosine kinase substrates based on protein kinase assay-linked phosphoproteomics.
    Xue L; Geahlen RL; Tao WA
    Mol Cell Proteomics; 2013 Oct; 12(10):2969-80. PubMed ID: 23793017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic identification of p38 MAP kinase substrates using in vitro phosphorylation.
    Iida N; Fujita M; Miyazawa K; Kobayashi M; Hattori S
    Electrophoresis; 2014 Feb; 35(4):554-62. PubMed ID: 24288278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Plant Kinase Substrates Based on Kinase Assay-Linked Phosphoproteomics.
    Hsu CC; Arrington JV; Xue L; Tao WA
    Methods Mol Biol; 2017; 1636():327-335. PubMed ID: 28730489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening.
    Peng H; Huang N; Qi J; Xie P; Xu C; Wang J; Yang C
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3693-9. PubMed ID: 14552760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics.
    Giansanti P; Preisinger C; Huber KV; Gridling M; Superti-Furga G; Bennett KL; Heck AJ
    ACS Chem Biol; 2014 Jul; 9(7):1490-8. PubMed ID: 24804581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.